Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...

WEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic acid might help slow the loss of ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...

Paramagnetic rim lesions and other imaging biomarkers that show up on MRI allow patients to be diagnosed and treated much ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

People who have been exposed to both PFAS and PCBs are more likely to be diagnosed with multiple sclerosis (MS). These new ...

FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...

Multiple sclerosis (MS) is a condition that affects your brain and spinal cord. It damages the myelin sheath, the tissue that surrounds and protects your nerve cells. This damage blocks or slows down ...

Heat sensitivity in multiple sclerosis is well known, but doctors say cold weather can also worsen symptoms. From nerve ...

7@four is joined by the team who will be serving the city and surrounding areas: Lead Nurse Practitioner Marion Thomas, ...